Dr. Shlomo Sadoun Joins Advisory Board

Argent Biopharma Limited

15 April 2024

 

15 April 2024

Argent BioPharma Ltd.

Dr. Shlomo Sadoun Joins Argent BioPharma Ltd Advisory Board

Argent BioPharma Ltd (Argent BioPharma or the Company), an innovative drug discovery company within the biopharmaceutical sector, is pleased to announce Dr. Shlomo Sadoun has joined Argent BioPharma's advisory board with immediate effect.

Dr. Shlomo Sadoun has over 18 years of experience in the pharmaceutical sector. Dr. Sadoun co-founded and leads SK-Pharma Group, a global pharmaceutical company operating in 18 countries. SK-Pharma specialises in producing and marketing generic, specialty pharma, hybrid generics, and biosimilar pharmaceutical products. Additionally, Dr. Sadoun serves as the CEO of Arphio, an orphan drug company utilising proprietary technology to promote, market, and sell orphan drugs worldwide.

Dr. Sadoun's expertise lies in leveraging technology to redefine business processes. He has established strategic alliances with over 200 innovative companies and launched more than 300 products globally, many of which were pioneering and branded. Dr. Sadoun's adeptness in utilising technological advancements has propelled SK-Pharma to become the fastest-growing pharmaceutical group in Israel and beyond. Dr. Sadoun holds a master's degree in Global Management from Salford University and a Doctorate in Business Administration from the Royal Academy of Economics and Technology in Switzerland, with a focus on public health.

Roby Zomer, Managing Director and CEO of Argent BioPharma, commented: "We are delighted to welcome Dr. Shlomo Sadoun, an esteemed addition to our advisory board. With his wealth of experience and expertise in the pharmaceutical sector, Dr. Sadoun will undoubtedly provide invaluable insights and guidance as we embark on our new strategic direction. His appointment reaffirms our commitment to fostering a diverse and knowledgeable advisory board, dedicated to driving innovation and growth in our Company."

-Ends-

Authorised for release by the board of directors, for further information please contact:

Argent BioPharma Roby Zomer CEO & Managing Director [phone] [e-mail]	Argent BioPharma Rowan Harland Company Secretary [phone] [e-mail]
UK IR/PR Advisers  IFC Advisory Graham Herring / Tim Metcalfe / Zach Cohen [phone] [e-mail]	UK Brokers Oberon Capital Aimee McCusker / Adam Pollock [phone] [e-mail] [e-mail]

About Argent BioPharma

Argent BioPharma is dedicated to meeting unmet medical needs by combining PolyPharmacology and Nanotechnology, aspiring to be a renowned global leader in the biopharmaceutical sector. Our mission centres on researching and developing ground-breaking treatments for worldwide health issues, guided by strategic principles such as pioneering life science advancements, ensuring global access, fostering continuous innovation, and striving for industry leadership.

 

END